
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded slow release capsule containing clonidine hydrochloride, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing clonidine are listed in tablet, patch, injection, solution and suspension forms. No finished clonidine product of any kind is listed in capsule form.
This is a solid, nonaqueous dose form. Under USP <795>, nonaqueous preparations carry longer default beyond-use dates than water-containing ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Clonidine is a centrally acting alpha-2 agonist blood pressure medicine that compounding pharmacies prepare as oral liquids, capsules, topical gels and other forms.
Clonidine is a centrally acting alpha-2 adrenergic agonist. It stimulates alpha-adrenoreceptors in the brain stem, which lowers the nervous system signals that tighten blood vessels and speed the heart, so blood pressure and heart rate fall. Manufactured products include clonidine hydrochloride tablets, Qlonilik oral solution, the Catapres-TTS weekly transdermal patch and Nexiclon XR extended-release tablets, all FDA-approved for hypertension; extended-release tablets and Onyda XR extended-release suspension approved for ADHD in children; and an epidural injection (Duraclon and generics) approved for severe cancer pain as an adjunct to opioids. A prescriber may order clonidine compounded when a patient needs a strength or dosage form that is not manufactured, cannot swallow tablets, or needs clonidine combined with another ingredient in one preparation. Compounded clonidine preparations are not FDA-approved and require a prescription.
Oral and transdermal clonidine carry no boxed warning. The epidural injection carries a boxed warning that it is not recommended for obstetrical, postpartum or perioperative pain because of the risk of severe low blood pressure and slow heart rate. For every form, the most important warning is about stopping suddenly: abrupt discontinuation can cause nervousness, headache and a rapid rise in blood pressure, so the label advises tapering over several days, especially at higher doses or with beta-blockers. Clonidine adds to the sedating effect of alcohol, barbiturates and other sedatives. Tricyclic antidepressants may blunt its blood pressure effect. With digoxin, beta-blockers, diltiazem or verapamil, heart rate should be monitored; severe slow heart rate needing a pacemaker has been reported with diltiazem or verapamil. People allergic to clonidine should not use it. The label says to use it in pregnancy only if clearly needed; it crosses the placenta. Clonidine passes into breast milk, and other blood pressure medicines are generally preferred while nursing a newborn. Common side effects are dry mouth, drowsiness, dizziness and constipation. If a side effect is severe or does not go away, or you faint or notice a slow or irregular heartbeat, talk to your prescriber or pharmacist.
Clonidine is a centrally acting alpha-2 adrenergic and imidazoline receptor agonist that reduces sympathetic outflow, lowering peripheral and renal vascular resistance, heart rate and blood pressure; in the spinal dorsal horn it reduces nociceptive transmission, which underlies epidural use. Oral absolute bioavailability is 70 to 80 percent with peak levels at 1 to 3 hours; the transdermal system delivers about 60 percent bioavailability over 7 days with therapeutic levels after 2 to 3 days. Protein binding is 20 to 40 percent. Elimination half-life is 12 to 16 hours, rising to about 41 hours in severe renal impairment; roughly half of an absorbed dose is metabolized hepatically and 40 to 60 percent is excreted unchanged in urine. Labeled indications: hypertension (Catapres-TTS, clonidine hydrochloride tablets), ADHD in children (the extended-release tablets labeled for ADHD and Onyda XR extended-release suspension; Nexiclon XR extended-release tablets are a hypertension product), and severe cancer pain unrelieved by opioids (epidural clonidine, Duraclon). Prescribers have ordered clonidine off-label for opioid, alcohol and benzodiazepine withdrawal, hot flashes, restless legs and migraine prophylaxis (StatPearls); no clonidine label lists Tourette tics, though StatPearls describes that use. Dosing and any taper are per prescriber; formulations are not interchangeable milligram for milligram. Monitor blood pressure and heart rate, screen for depression, and plan a gradual taper. Clonidine is not a controlled substance.
Swallow the capsule whole with fluid. Do not crush, chew, divide or open it, and do not dissolve it in liquid, because that can release the full dose at once. Take it at the same times each day as your label directs. Slow release forms are not meant for feeding tubes; ask your pharmacist if you need a different form.
These are nonaqueous capsules, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in a closed container at room temperature, away from heat, moisture and direct light, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Take 1 capsule by mouth